CCMW
BCLI

Cypress Capital Management (Wyoming)’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Cypress Capital Management (Wyoming)’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-667
Closed -$5.65K – 167
2024
Q1 		$5.65K Hold
667
– – 0.01% 122
2023
Q4 		$2.73K Buy
667
+467
+234% +$1.4K ﹤0.01% 134
2023
Q3 		$600 Buy
200
+133
+199% +$3.02K ﹤0.01% 162
2023
Q2 		$2.06K Buy
+67
New +$2.78K ﹤0.01% 144
2022
Q4 		– Sell
-1,067
Closed -$71K – 164
2022
Q3 		$71K Buy
1,067
+1,000
+1,493% +$50.2K 0.1% 59
2022
Q2 		$3K Buy
+67
New +$3.02K ﹤0.01% 144
2022
Q1 		– Sell
-100
Closed -$6K – 185
2021
Q4 		$6K Buy
+100
New +$4.92K 0.01% 216
2021
Q3 		– Sell
-67
Closed -$4K – 247
2021
Q2 		$4K Hold
67
– – ﹤0.01% 264
2021
Q1 		$4K Hold
67
– – ﹤0.01% 244
2020
Q4 		$5K Buy
67
+34
+103% +$4.63K ﹤0.01% 208
2020
Q3 		$9K Hold
33
– – 0.01% 162
2020
Q2 		$6K Buy
+33
New +$3.56K 0.01% 175

Other funds holding BCLI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 22.73% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Cypress Capital Management (Wyoming)'s BCLI Position: Q2 2024 in Review

Cypress Capital Management (Wyoming) sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2024, closing a stake of 667 shares — an estimated $5.65K sold.

Cypress Capital Management (Wyoming) first reported a position in BCLI in Q2 2020 and held it in 12 quarters. The position peaked at $71K in Q3 2022. 48 funds tracked by Wall St. Rank hold BCLI as of Q2 2024.

  • Cypress Capital Management (Wyoming) reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2024 after selling out during the quarter.
  • Cypress Capital Management (Wyoming) sold 667 BRAINSTORM CELL THERAPUTC shares in Q2 2024, an estimated $5.65K.
  • Cypress Capital Management (Wyoming) first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2020 and held it in 12 quarters.
  • Cypress Capital Management (Wyoming)'s BRAINSTORM CELL THERAPUTC position peaked at $71K in Q3 2022.
  • 48 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2024.

Based on Cypress Capital Management (Wyoming)'s 13F filing for Q2 2024, filed 5 Aug 2024.